European Foundation For The Study Of Chronic Liver Failure
- Address
- Travessera De Gracia 11 7th Floor
Sponsor Overview
Specializations
Cirrhosis and Decompensated Liver Disease
Clinical research is centered on cirrhosis, with a particular focus on patients experiencing decompensated cirrhosis and advanced chronic liver failure. The studies address complicated disease states associated with poor clinical outcomes and worsening liver function.
- Decompensated cirrhosis
- Chronic liver failure
- Advanced liver complications
The sponsor’s trial portfolio includes multicountry research across Europe, reflecting an interest in clinically challenging forms of liver disease that require specialized therapeutic strategies.
Human Albumin Therapy
A major therapeutic area is human albumin administration in patients with cirrhosis and its complications, including ascites. The research explores personalized use of albumin in routine management and in patients with more complex disease profiles.
- Albumin-based treatment
- Ascites management
- Personalized albumin administration
These studies examine the role of albumin therapy in improving care for patients with fluid-related complications of liver cirrhosis.
Combination Therapy in Portal Hypertension-Related Disease
The sponsor also supports research into a combinatorial approach using human albumin with enoxaparin for patients at high risk of poor outcome. This area reflects interest in treatment strategies that combine supportive and antithrombotic management in advanced liver disease.
- Albumin and enoxaparin
- Combination treatment strategies
- High-risk cirrhosis
The therapeutic emphasis is on patients with severe cirrhosis who may benefit from integrated approaches targeting complications linked to disease progression.
Biomarker-Guided Treatment Response
Another key area is the validation of a predictive biomarker for treatment response to human albumin in patients with cirrhosis and ascites. This research focuses on identifying which patients are most likely to benefit from albumin-based therapy.
- Predictive biomarker
- Treatment response assessment
- Cirrosis with ascites
These studies are directed toward more individualized care in hepatology, with attention to patient selection in albumin-treated disease.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| ALB-TRIAL: Personalized Long-term Human Albumin Treatment in Patients With Decompensated Cirrhosis and Ascites |  Belgium Denmark Germany Hungary Spain The Netherlands | Not Yet Recruiting |
| Biomarker‑Guided Personalized Human Serum Albumin Therapy in Decompensated Cirrhosis with Ascites: A Multinational Randomized Controlled Trial | Belgium Denmark Germany Hungary Slovakia Spain The Netherlands | Recruiting |
| Evaluation of Enoxaparin Sodium and Human Serum Albumin Combination Therapy in High-Risk Decompensated Cirrhosis Patients |  France Germany Italy Spain | Not Recruiting |
Data & Insights
This sponsor works with 3 molecules, of which 0 are not being studied by other sponsors.
This sponsor has worked with 19 sites across their trial portfolio.
Therapeutic Focus
- 1.Digestive System Diseases3 trials280 other sponsors
Partnered Research Centres
19 centres- Address
- Albinusdreef 2, 2333 ZA Leiden
- Address
- Simon Smitweg 1, 2353 GA Leiderdorp
- Address
- Via Cherasco 15, 10126 Turin
- Address
- Via Pietro Albertoni 15, 40138 Bologna
- Address
- Augustenburger Platz 1, 13353 Berlin
- Address
- Namestie Ludvika Svobodu 1, 974 01 Banská Bystrica
Want to get in touch with this sponsor?
Send a question and we'll pass it on to European Foundation For The Study Of Chronic Liver Failure.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.